Interestingly, comparative trials of various agents in rheumatoid arthritis suggest that agents such as these (e.g. etanercept, certolizumab) are superior to those targeting other cytokines such as IL-1 (e.g. anakinra) [69], which reside further upstream in our models. The gene discussed is IL1A; the disease is rheumatoid arthritis.